XML 77 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - License Agreements (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jul. 28, 2023
Jul. 31, 2020
Dec. 31, 2012
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2018
Jan. 31, 2018
Sep. 22, 2014
Jan. 31, 2012
Income Tax Expense (Benefit)       $ 390 $ 0 $ 0        
Deferred Revenue       300            
L F B License Agreement [Member]                    
License And Collaboration Agreement, Expenses Incurred       31,000            
Accounts Payable       0            
Royalty Expense       8,700            
Accrued Royalties       3,900            
L F B License Agreement [Member] | License Agreement Terms [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)                   15 years
L F B License Agreement [Member] | Maximum [Member]                    
Additional Amount Receivable on Achievement of Pre-specified Milestones                   $ 6,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member]                    
Additional Amount Receivable on Achievement of Pre-specified Milestones     $ 5,000              
Upfront Fee Received From Sub License     2,000              
Income Tax Expense (Benefit)     $ 300              
License Revenue       200 200 200        
Deferred Revenue         500          
Sublicense Agreement With Ildong Pharmaceutical Co [Member] | License Agreement Terms [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)     15 years              
Commercialization Agreement With Neuraxpharm [Member]                    
Additional Amount Receivable on Achievement of Pre-specified Milestones $ 492,500                  
License and Collaboration Agreements, One-time, Non-refundable Payment 140,000     140,000            
Additional Payments Upon Key Market Commercial Launch $ 12,500                  
Royalty Percentage on Net Product Sales 30.00%                  
Agreement Buyback Period (Year) 2 years                  
TG 1701 [Member]                    
Additional Amount Payable on Achievement of Pre-specified Milestones               $ 350,000    
TG 1701 [Member] | Hengrui [Member]                    
Milestone Payments   $ 2,000                
TG 1801 [Member]                    
Additional Amount Payable on Achievement of Pre-specified Milestones             $ 185,000      
The Umbralisib License [Member]                    
License And Collaboration Agreement, Expenses Incurred       24,000            
Royalty Expense       0            
Additional Amount Payable on Achievement of Pre-specified Milestones                 $ 175,000  
The Umbralisib License [Member] | Rhizen [Member]                    
Milestone Payments           12,000        
TG 1501 [Member]                    
License And Collaboration Agreement, Expenses Incurred       $ 100 $ 100 $ 100